Structure-activity analysis of C-terminal endothelin analogues

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• Endothelin (ET) is a potent vasoconstrictor.
• The C-terminal hexapeptide (ET16-21) is crucial for ET activity.
• Understanding ET structure-activity relationships is vital for therapeutic development.

Purpose of the Study:

• To synthesize and characterize novel ET analogues.
• To investigate the role of specific residues in ET receptor binding and biological activity.
• To develop a monoclonal antibody against ET and assess its neutralizing capacity.

Main Methods:

• Radio-receptor competition binding assays for ETA and ETB subtypes.
• Monoclonal antibody production (anti-ET15-21) and characterization.
• Enzyme-linked immunosorbent assays (ELISA) and surface plasmon resonance (SPR) for antibody binding.
• Alanine scanning (Ala-scan) and non-amino acid substitutions of ET16-21.

Main Results:

• C-terminal residues (Asp18, Ile20, Trp21) are critical for receptor binding and antibody recognition.
• Modifications at positions 16, 17, and 19 of ET16-21 had minimal impact on activity.
• The last two C-terminal residues are essential for both receptor and antibody binding.
• A specific steric conformation of the hexapeptide is necessary for activity.

Conclusions:

• The C-terminal region of ET16-21 is essential for its biological and immunological functions.
• The antibody anti-ET15-21 effectively neutralizes ET activity.
• Structure-activity relationship studies reveal key residues for ET receptor and antibody interactions.